相似文献
1
[Treatment with low doses of intravenous iron does not modify hemoglobin nor the erythropoietin dosage].
Nefrologia. 2006;26(1):143-4.
2
Response to EPO therapy.
Przegl Lek. 1992;49(1-2):36-7.
3
Management of anemia of chronic renal failure.
J Assoc Physicians India. 1999 Feb;47(2):216-23.
4
5
[Treatment with intravenous iron and ferritin level].
Nefrologia. 2010;30(3):371-2. doi: 10.3265/Nefrologia.pre2010.Mar.10258.
6
[Treatment of anemia in chronically dialyzed patients].
Nephrologie. 1998;19(3):125-7.
7
A comprehensive vision for intravenous iron therapy.
Am J Kidney Dis. 2008 Dec;52(6 Suppl):S14-20. doi: 10.1053/j.ajkd.2008.09.003.
8
[Anemia in terminal kidney failure. Pathogenesis and therapy].
Fortschr Med. 1977 Feb 10;95(6):338-44.
9
Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Am J Kidney Dis. 2006 Jun;47(6):1027-35. doi: 10.1053/j.ajkd.2006.02.176.
10
Use of red blood cell indices (MCV, MCH, RDW) in monitoring chronic hemodialysis patients treated with recombinant erythropoietin.
Pathol Biol (Paris). 1993 Dec;41(10):931-5.
Zotero 插件